Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, after Alzheimer’s disease. PD is characterised by a gradual loss of dopaminergic neurons in the substantia nigra as well as the accumulation of abnormal clumps of alpha-synuclein in the brain. Decreased dopamine levels lead to the cardinal motor symptoms of Parkinson’s disease, which include resting tremor, bradykinesia, stiffness of the limbs (cogwheel rigidity) and postural instability.1
Recently, Linical was featured in an article in International Clinical Trials, written by Rebecca Evans, MD. The article looks at how specific new technologies and innovations could redefine how Parkinson’s disease trials are designed and conducted. Dr Evans, shares her thoughts on how evolution in trial conduct, methodology and operational complexity is expected over the coming years and the impact this will have on Parkinson's disease trial design.
This article is taken from International Clinical Trials, November 2025, pages 40-42 . © Samedan Ltd
References:
1. Visit: pubmed.ncbi.nlm.nih.gov/18344392/